Real-World Analysis of Teclistamab Treatment for Relapsed Refractory Multiple Myeloma in Two Belgian University Hospitals

被引：0
|
作者：
Jadot, Gaspard [1 ]
Depaus, Julien [2 ]
Vekemans, Marie-Christiane [2 ,3 ]
机构：
[1] Clin Univ St Luc, Brussels, Belgium
[2] Univ Catholic Louvain, Dept Haematol, CHU UCL Namur, Yvoir, Belgium
[3] Univ Catholic Louvain, UCLouvain, Brussels, Belgium
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-032
引用
收藏
页码：S59 / S59
页数：1
相关论文
共 50 条
  • [41] Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
    Huang, Shang-Yi
    Chen, Tsai-Yun
    Kuo, Ching-Yuan
    Chen, Yeu-Chin
    Lin, Sheng-Fung
    Chang, Ming-Chih
    Lv, Xinzhu
    Yang, Betty
    Chang, Cheng-Shyong
    ONCOLOGY REVIEWS, 2019, 13 (01) : 15 - 22
  • [42] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
    Hultcrantz, Malin
    Orozco, Jennifer
    Peterson, Tim J.
    Derkach, Andriy
    Hassoun, Hani
    Korde, Neha
    Lu, Sydney X.
    Mailankody, Sham
    Patel, Dhwani
    Shah, Urvi A.
    Tan, Carlyn
    Maclachlan, Kylee H.
    Chung, David J.
    Landau, Heather J.
    Shah, Gunjan L.
    Lahoud, Oscar B.
    Scordo, Michael
    Landgren, Ola
    Giralt, Sergio
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [43] Real-World Practice Patterns with Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma
    Harvey, R. Donald
    Cong, Ze
    Werther, Winifred
    Lethen, Jan L.
    Lonial, Sagar
    BLOOD, 2014, 124 (21)
  • [44] Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice
    Hulin, Cyrille
    de la Rubia, Javier
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Katodritou, Eirini
    Hungria, Vania
    De Samblanx, Hadewijch
    Stoppa, Anne-Marie
    Aagesen, Jesper
    Sargin, Deniz
    Sioni, Anastasia
    Belch, Andrew
    Diels, Joris
    Olie, Robert A.
    Robinson, Don, Jr.
    Potamianou, Anna
    van de Velde, Helgi
    Delforge, Michel
    HEALTH SCIENCE REPORTS, 2019, 2 (01)
  • [45] Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/ Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
    Rodriguez-Otero, Paula
    Sirvent, Maialen
    Pilar Gonzalez-Rodriguez, Ana
    Lavilla, Esperanza
    Garcia de Coca, Alfonso
    Maria Arguinano, Jose
    Marti, Josep M.
    Cabanas, Valentin
    Motllo, Cristina
    de Cabo, Erik
    Encinas, Cristina
    Murillo, Ilda
    Angel Hernandez-Rivas, Jose
    Perez-Persona, Ernesto
    Casado, Felipe
    Sampol, Antonia
    Garcia, Ricarda
    Jesus Blanchard, Maria
    Anguita, Magdalena
    Paz Lafuente, Ana
    Inigo, Belen
    Lopez, Aurelio
    Ribas, Paz
    Arnao, Mario
    Maldonado, Roberto
    Blade, Joan
    Victoria Mateos, Maria
    Jose Lahuerta, Juan
    San Miguel, Jesus F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (06): : 413 - 420
  • [46] Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients
    Lovas, Szilvia
    Varga, Gergely
    Farkas, Peter
    Masszi, Tamas
    Wohner, Nikolett
    Bereczki, Agnes
    Adamkovich, Nora
    Borbenyi, Zita
    Szomor, Arpad
    Alizadeh, Hussain
    Szaleczky, Erika
    Wolf, Krisztina
    Schneider, Tamas
    Plander, Mark
    Szendrei, Tamas
    Csacsovszki, Otto
    Csukly, Zoltan
    Rajnics, Peter
    Egyed, Miklos
    Nagy, Zsolt
    Rejto, Laszlo
    Illes, Arpad
    Mikala, Gabor
    Varoczy, Laszlo
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (05) : 559 - 565
  • [47] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
    Cavo, Michele
    Delforge, Michel
    Dimopoulos, Meletios
    Escalante, Fernando
    Hultcrantz, Malin
    Kleinman, David
    Lee, Hans
    Vij, Ravi
    Kotowsky, Nirali
    Camadoo-O'Byrne, Leena
    Bitetti, Jacopo
    D'Estrube, Tim
    Fry, Mark
    Vossen, Carla
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167
  • [48] Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients
    Szilvia Lovas
    Gergely Varga
    Péter Farkas
    Tamás Masszi
    Nikolett Wohner
    Ágnes Bereczki
    Nóra Adamkovich
    Zita Borbényi
    Árpád Szomor
    Hussain Alizadeh
    Erika Szaleczky
    Krisztina Wolf
    Tamás Schneider
    Márk Plander
    Tamás Szendrei
    Ottó Csacsovszki
    Zoltán Csukly
    Péter Rajnics
    Miklós Egyed
    Zsolt Nagy
    László Rejtő
    Árpád Illés
    Gábor Mikala
    László Váróczy
    International Journal of Hematology, 2019, 110 : 559 - 565
  • [49] Real-World Study of Treatment Patterns in Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM) in the US
    Wang, Peter Feng
    Sansbury, Leah
    DerSarkissian, Maral
    Ferrante, Shannon
    Bhak, Rachel
    Gorsh, Boris
    Zichlin, Miriam L.
    Yee, Christopher W.
    Boytsov, Natalie
    Khanal, Anamika
    Paka, Prani
    Noman, Ahmed
    Duh, Mei Sheng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S423
  • [50] Comparative effectiveness of teclistamab versus real-world treatments for patients with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).
    Krishnan, Amrita Y.
    Nooka, Ajay K.
    Chari, Ajai
    Garfall, Alfred L.
    Martin, Thomas G.
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Pei, Lixia
    Eric, Ammann
    Kobos, Rachel
    Smit, Jennifer
    Parekh, Trilok V.
    Slavcev, Mary
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345